In 2023, the treatment success rate for patients with multidrug-resistant tuberculosis (MDR-TB) in the UK stood at 74%. Forecast data shows a steady increase from 2024 through 2028, starting at 76% and reaching 82%, marking a consistent year-on-year improvement of approximately 1.5% to 2.5%. The compound annual growth rate (CAGR) over this five-year period is estimated at about 2%.

Looking forward, several factors could influence these trends:

New treatment breakthroughs and their implementation.
Government and healthcare sector policies affecting TB treatment access and affordability.
Emerging global health trends and their impact on MDR-TB dynamics.